B
HBIO icon

Bailard’s Harvard Bioscience HBIO Stock Holding History

Bailard’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,323
Closed -$56.1K – 765
2024
Q1 		$56.1K Sell
1,323
-649
-33% -$29.2K ﹤0.01% 727
2023
Q4 		$106K Buy
+1,972
New +$89K ﹤0.01% 691
2022
Q3 		– Sell
-2,685
Closed -$97K – 703
2022
Q2 		$97K Buy
+2,685
New +$121K ﹤0.01% 652
2022
Q1 		– Sell
-1,470
Closed -$104K – 762
2021
Q4 		$104K Buy
+1,470
New +$105K ﹤0.01% 708
2020
Q4 		– Sell
-1,850
Closed -$56K – 650
2020
Q3 		$56K Buy
+1,850
New +$62.2K ﹤0.01% 545

Other funds holding HBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2C
272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Bailard's HBIO Position: Q2 2024 in Review

Bailard sold out of Harvard Bioscience (HBIO) in Q2 2024, closing a stake of 1,323 shares — an estimated $56.1K sold.

Bailard first reported a position in HBIO in Q3 2020 and held it in 5 quarters. The position peaked at $106K in Q4 2023. 100 funds tracked by Wall St. Rank hold HBIO as of Q2 2024.

  • Bailard reported no remaining Harvard Bioscience position as of Q2 2024 after selling out during the quarter.
  • Bailard sold 1,323 Harvard Bioscience shares in Q2 2024, an estimated $56.1K.
  • Bailard first reported a position in Harvard Bioscience in Q3 2020 and held it in 5 quarters.
  • Bailard's Harvard Bioscience position peaked at $106K in Q4 2023.
  • 100 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2024.

Based on Bailard's 13F filing for Q2 2024, filed 25 Jul 2024.